News

Following years of concerns about the stigmatization and inaccurate etiology of nonalcoholic fatty liver disease nomenclature, 2023 finally saw revised terminology for liver disease with the implementation of metabolic dysfunction-associated steatotic liver disease.

Patients with gout achieving target serum uric acid levels showed good adherence to urate-lowering therapy, used antihypertensive agents, and lacked a family history of gout.

A cohort of patients with end-stage renal disease on maintenance hemodialysis saw a 7% reduction in HCV-viremic rate and primary infection rates as low as 0.01% following implementation of the link-to-treat program.

Late shift work is associated with sleep disorders the most for females, the age group <30 years old, people who live alone or with roommates, have only up to an elementary or secondary education, and people who work the night shift.

In recent conversations with experts in epilepsy, the impact of stigmatization remains high for patients and ongoing efforts by clinicians to address this issue in the clinical setting has been underscored, despite the global lack of awareness about new treatments and other resources.

Adding navy beans to one’s usual diet may be a viable dietary strategy for modulating the gut microbiome and regulating host markers associated with metabolic obesity and colorectal cancer.

Guizhi-Shaoyao-Zhimu Decoction treatment helps lower levels of blood uric acid, c-reactive proteins, erythrocyte sedimentation rate, interleukin 6, interleukin 8, tumor necrosis factor, and visual analogue scale more than conventional treatment for gout.

This analysis resulted in several valuable insights related to the landscape of gout patients’ changes in their blood immune cells between flares and periods of remission.

Waist circumference and high lipid levels were associated with poor disease outcomes in gout, including flares and failure to achieve treatment target.

Results from the MOMPOD RCT indicate metformin added to insulin did not reduce the frequency of a composite adverse neonatal outcome in pregnant adults with diabetes.

This new data expanded upon research into gout’s molecular pathogenesis and into ULT for managing non-gout diseases such as hyperuricemia.

Patients with the highest Dietary Inflammatory Index have an increased risk of gout.

Presented at ASH 2023, findings of a new study showed patients with sickle cell disease and venous thromboembolism have longitudinal worsening of left ventricular diastolic and right-sided cardiac function.

A virtual screening combined with experimental verification identified the potential mechanism of fuzitang decoction in the treatment of Gouty Arthritis.

In a new study, a subgroup analysis demonstrated a reduced risk of colorectal cancer among patients <65 years old with gout.

Nonsteroidal anti-inflammatory drug use and prednisolone equivalent dose >5 mg per day were associated with an increased risk of NAFLD, whereas hydroxychloroquine use and prednisolone equivalent dose ≤5 mg per day were associated with a decreased risk of NAFLD.

The submissions to both agencies were based upon positive results from the BASIS trial that had been presented at the American Society of Hematology Annual Meeting.

Phase 3 data presented at ASH 2023 show the gene therapy significantly reduced annualized bleeding rates and the number of total bleeds.

Final emergency department pain scores, opioid doses in the emergency department, and receipt of an opioid prescription at discharge predicted hospitalization and return visits.

Presented at ASH 2023, opioid use disorder in sickle cell disease patients with vaso-occlusive is associated with a longer hospital stay and greater cost.

A higher prevalence of STI diagnosis is observed in adolescents and young adults with sickle cell disease compared with controls.

Multinational data support the safety of drug classes like GLP-1 agonists during early relative to infant risk of major congenital malformations.

Phase 3 data show patients with obesity who maintained tirzepatide from weeks 36 to 88 continued significant weight loss versus patients switched to placebo.

Given the lack of widespread awareness of the magnitude and prevalence of the public’s stigma toward people with acne, this research sought to expand upon this body of research.

It is common for patients with rheumatoid arthritis to have mental health conditions. Test your knowledge of the impact of anxiety and depression in rheumatoid arthritis with this quiz.

Findings of a new study suggest COVID-19 does not serve as risk factor for the development of VTE in pediatric cancer patients.

Results showed treatment with iptacopan through 48 weeks caused hemoglobin-level increases, blood transfusion avoidance, and reductions in patient-reported fatigue.

2023 was a year of both advancements and setbacks for various treatments, and this discussion covers the most significant moves by the FDA this year.

Just 8.5% of eligible patients were screened for hepatitis C - among them, 5.9% tested positive for HCV antibody and 3.0% had an active infection.

Although more than half of female patients with sickle cell disease reported sickle cell pain associated with their menstrual cycles, only 12.5% had used ≥1 hormonal therapies within the past 3 months.